[N:1]1[N:5]2[N:6]=[CH:7][CH:8]=[CH:9][C:4]2=[C:3]([C:10]2[CH:15]=[CH:14][C:13]([CH2:16][C:17]([OH:19])=O)=[CH:12][CH:11]=2)[CH:2]=1.[Cl-].[Cl-].[NH3+:22][C@@H:23]([C:25]1[CH:30]=[CH:29][C:28]([O:31][CH2:32][C:33]([F:36])([F:35])[F:34])=[CH:27][NH+:26]=1)[CH3:24].C1C=NC2N(O)N=NC=2C=1.C(Cl)CCl.CCN(C(C)C)C(C)C>C(Cl)Cl>[N:1]1[N:5]2[N:6]=[CH:7][CH:8]=[CH:9][C:4]2=[C:3]([C:10]2[CH:11]=[CH:12][C:13]([CH2:16][C:17]([NH:22][C@@H:23]([C:25]3[CH:30]=[CH:29][C:28]([O:31][CH2:32][C:33]([F:36])([F:34])[F:35])=[CH:27][N:26]=3)[CH3:24])=[O:19])=[CH:14][CH:15]=2)[CH:2]=1To a solution of 0.69 g (2.74 mmol) (4-pyrazolo[1,5-b]pyridazin-3-ylphenyl)acetic acid in 10.0 ml CH2Cl2 was added 0.96 g (3.28 mmol) of 2-[(1R)-1-ammonioethyl]-5-(2,2,2-trifluoroethoxy)pyridinium dichloride, 0.48 g (3.56 mmol) of HOAt, 0.68 g (3.56 mmol) of EDC, and 1.43 mL (8.21 mmol) of DIEA. After 1 h at room temperature, the reaction mixture was diluted with CH2Cl2, washed three times with water, and washed with brine. The organic layer was dried over Na2SO4, filtered and concentrated in vacuo. Purification by flash chromatography (silica gel, gradient 0-100% EtOAc in hexanes) afforded 0.85 g (68%) of 2-(4-pyrazolo[1,5-b]pyridazin-3-ylphenyl)-N-{(1R)-1-[5-(2,2,2-trifluoroethoxy)pyridin-2-yl]ethyl}acetamide. 1H NMR (CD3OD, 400 MHz) 8.40 (m, 2-H); 8.28 (s, 1H); 8.27 (d, J=2.93 Hz, 1H); 7.61 (dd, J=1.83, 6.41 Hz, 2H); 7.43 (m, 3H); 7.31 (d, J=8.61 Hz, 1H); 7.22 (dd, J=4.58, 9.07 Hz, 1H); 5.04 (quintet, J=6.86 Hz, 1H); 4.62 (q, J=8.43 Hz, 2H); 3.61 (s, 2H); 1.46 (d, J=7.05 Hz, 31-1). HRMS (ES) [M+1]+calcd for C23H21F3N5O2: 456.1647, Found: 456.1652. FLEPR alpha1I IP=5.0 nM.